Table 1.
Baseline Characteristics, Systemic Imaging, and Outcomes of the Multicenter Cohort of Patients with a Positive Diagnosis of Primary CNS Diffuse Large B-Cell Lymphoma
| Parameters | Asan Medical Center (n = 301) |
Samsung Medical Center (n = 280) |
Yonsei University Severance Hospital (n = 184) |
Seoul National University Hospital (n = 69) |
Brigham and Women’s Hospital (n = 209) |
Total (n = 1043) |
|---|---|---|---|---|---|---|
| Baseline | ||||||
| Age, mean (SD), year | 59(13) | 59 (13) | 61 (13) | 61 (12) | 65 (12) | 61 (13) |
| Sex, no. (%) | ||||||
| Women | 123 (40.9%) | 131 (46.8%) | 91 (49.5%) | 34 (49.3%) | 103 (49.3%) | 483 (46.3%) |
| Men | 178 (59.1%) | 149 (53.2%) | 93 (50.5%) | 35 (50.7%) | 106 (50.7%) | 561 (53.7%) |
| EBV-positive | 14 (4.7%) | 8 (2.9%) | 2 (1.1%) | NA | 12 (5.7%) | 36 (3.8%) |
| EBV-negative | 200 (66.4%) | 200 (71.4%) | 84 (45.7%) | NA | 110 (52.6%) | 594 (60.9%) |
| EBV not evaluated | 87 (28.9%) | 72 (25.7%) | 98 (53.3%) | NA | 87 (41.6%) | 344 (35.3%) |
| Systemic imaging | ||||||
| Contrast-enhanced chest/abdomen/pelvis CT | 299 (99.3%) | 278 (99.3%) | 158 (85.9%) | 21 (30.4%) | 164 (78.5%) | 920 (88.2%) |
| Whole-body PET/CT | 251 (83.4%) | 249 (88.9%) | 129 (70.1%) | 63 (91.3%) | 162 (77.5%) | 854 (80.6%) |
| Testicular US | 7 of 178 (4.0%) | 7 of 149 (4.7%) | 3 of 93 (3.2%) | 0 of 35 (0%) | 55 of 106 (51.9%) | 72 of 561 (12.8%) |
| Outcomes | ||||||
| True-positive | 6 of 301 (2.0%, 0.7–4.3%) | 7 of 280 (2.5%, 1.0–5.1%) | 6 of 184 (3.3%, 1.2–7.0%) | 0 of 69 (0.0%, 0.0–5.2%) | 8 of 209 (3.8%, 1.7–7.4%) | 27 of 1043 (2.6%, 1.7–3.7%) |
| False-positive | 12 of 301 (4.0%, 2.1–6.9%) | 17 of 280 (6.1%, 3.6–9.5%) | 8 of 184 (4.3%, 1.9–8.4%) | 5 of 69 (7.2%, 2.4–16.1%) | 18 of 209 (8.6%, 5.2–13.3%) | 60 of 1043 (5.8%, 4.4–7.3%) |
| Subgroup analysis (true-positive) | ||||||
| Patients > 61 years old | 4 of 132 (3.0%, 0.8–7.6%) | 5 of 127 (3.9%, 1.3–9.0%) | 6 of 96 (5.6%, 2.3–13.1%) | 0 of 34 (0.0%, 0.0–10.3%) | 6 of 135 (4.4%, 1.7–9.4%) | 21 of 524 (4.0%, 2.5–6.1%) |
| Patients ≤ 61 years old | 2 of 169 (1.2%, 0.1–4.2%) | 2 of 153 (1.3%, 0.2–4.6%) | 0 of 88 (0.0%, 0.0–4.1%) | 0 of 35 (0.0%, 0.0–10.0%) | 2 of 74 (2.7%, 0.3–9.4%) | 6 of 519 (1.2%, 0.4–2.5%) |
| EBV-positive DLBCL | 1 of 14 (7.1%, 0.2–33.9%) | 0 of 8 (0%, 0.0–36.9%) | 0 of 2 (0.0%, 0.0–84.2%) | NA | 2 of 12 (16.7%, 2.1–48.4%) | 3 of 36 (8.3%, 1.8–22.5%) |
| EBV-negative DLBCL | 4 of 200 (1.6%, 0.6–5.0%) | 5 of 200 (2.5%, 0.8–5.7%) | 1 of 84 (1.2%, 0.3–8.3%) | NA | 6 of 110 (5.5%, 2.0–11.5%) | 16 of 594 (2.7%, 1.6–4.3%) |
| DLBCL without EBV status | 1 of 87 (1.2%, 0.3–6.2%) | 2 of 72 (2.8%, 0.3–9.7%) | 5 of 98 (5.1%, 1.7–11.5%) | NA | 0 of 87 (0.0%, 0.0–4.2%) | 8 of 344 (2.3%, 1.0–4.5%) |
| Other outcome | ||||||
| Other malignancy detected by whole-body PET/CT | 7 of 251 (2.8%, 1.1–5.7%) | 2 of 249 (0.8%, 0.1–2.9%) | 1 of 129 (0.8%, 0.0–4.2%) | 1 of 63 (1.6%, 0.0–8.5%) | 2 of 162 (1.2%, 0.2–4.4%) | 13 of 854 (1.5%, 0.8–2.6%) |
Abbreviations: CT, computed tomography; PET, positron emission tomography; SD, standard deviation; US, ultrasound
Data are numbers with percentages in parentheses.